FILTERS
TOPICS
CritiTech PES partner NanOlogy Announces Initiation of a Lung Cancer Clinical Trial Following FDA Allowances of Two IND Applications for NanoPac® in Lung Cancer
First-in-human clinical trial of intratumoral (IT) injections of NanoPac in non-small cell lung cancer (NSCLC) and small cell lung cancer … Continued
More >CritiTech PES partner NanOlogy Presents Updated Clinical Data on Targeted Injections of NanoPac® for Pancreatic Cancer and Mucinous Cystic Neoplasms on DDW2020 Site
Updated clinical data from both trials available through Digestive Disease Week® (DDW) Online Education Site FT. WORTH, (May 14, 2020) — NanOlogy, … Continued
More >NanOlogy Fact Sheet (Jan 2020)
In patients with solid carcinomas, NanOlogy™ has demonstrated that local administration of patented submicron particles continuously exposes primary tumors to … Continued
More >Video Highlights of NanoPac® Injection for Pancreatic Cancer
Highlights of the presentation by Dr. Neil Sharma, President, Parkview Cancer Institute; Director of Advanced Interventional Endoscopy and Endoscopic Oncology … Continued
More >ACG 2019 Poster: NanoPac-2017-01 Mid-Study Report: Safety, Tolerability and Preliminary Efficacy of Intracyctic Submicron Particle Paclitaxel (SPP) for the Treatment of Pancreatic Mucinous Cysts
Slide 1 Pancreatic mucinous cystic lesions have significant potential for malignant transformation1; delivery of SPP as a direct intratumoral injection … Continued
More >ACG 2019 Plenary Presentation: A Novel EUS-guided Intratumoral Delivery of Submicron Particle Paclitaxel for the Treatment of Locally Advanced Pancreatic Cancer
A novel EUS-guided Intratumoral Delivery of Submicron Particle Paclitaxel for the Treatment of Locally Advanced Pancreatic Cancer. A Prospective Safety, … Continued
More >CritiTech PES partner NanOlogy’s Clinical Updates on Local Injection of NanoPac® for Pancreatic Cancer and Mucinous Cystic Neoplasms of the Pancreas
Interim data from both clinical trials presented at the 2019 American College of Gastroenterology (ACG) Conference in San Antonio November … Continued
More >Positive Preclinical Findings from Inhaled NanoPac® Lung Study Published in the Journal of Aerosol Medicine and Pulmonary Drug Delivery
Preclinical Study Demonstrated Inhaled NanoPac Shows Prolonged Retention and Limited Systemic Exposure FORT WORTH/DALLAS, (October 30, 2018) — NanOlogy, a clinical-stage … Continued
More >DFB Soria Completes a Phase 2 Clinical Trial of Submicron Particle Paclitaxel Anhydrous Ointment for Actinic Keratosis
Soria investigational drug provides evidence of actinic keratosis (AK) lesion reduction without the local irritation of approved topical AK treatment … Continued
More >CritiTech PES partner NanOlogy Adds Clinical Trial Sites for Phase 2 Clinical Trials of NanoPac® in Pancreatic Cancer and Pancreatic Mucinous Cysts
Preliminary Data from Both Trials Show NanoPac Well-Tolerated via Intratumoral and Intracystic Injection FORT WORTH/DALLAS, (August 8, 2018) — NanOlogy LLC, … Continued
More >